(NMRA) Neumora Therapeutics - Performance -89.1% in 12m
NMRA performance: live returns, drawdowns, peer ranking & SPY comparison from 1w to 5y, all in one clean chart-driven dashboard.
Performance Rating
-56.01%
#125 in Peer-Group
Rel. Strength
1.34%
#7560 in Stock-Universe
Total Return 12m
-89.06%
#195 in Peer-Group
Total Return 5y
-92.53%
#166 in Peer-Group
| P/E | Value |
|---|---|
| P/E Trailing | - |
| P/E Forward | - |
| High / Low | USD |
|---|---|
| 52 Week High | 16.96 USD |
| 52 Week Low | 0.62 USD |
| Sentiment | Value |
|---|---|
| VRO Trend Strength +-100 | 92.69 |
| Buy/Sell Signal +-5 | 2.61 |
| Support / Resistance | Levels |
|---|---|
| Support | |
| Resistance |
12m Total Return: NMRA (-89.1%) vs XLV (-7.1%)
5y Drawdown (Underwater) Chart
Top Performer in Pharmaceuticals
Overall best picks of Peer Group - Selected by proven GARP Predictive Metrics, sorted by Growth Rating
| Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability | EPS CAGR |
|---|---|---|---|---|---|---|---|---|
| CORT NASDAQ Corcept Therapeutics |
2.64% | 125% | 343% | 62.6 | 55.3 | 0.61 | 23.7% | -5.15% |
| NVS NYSE Novartis |
2.5% | 13.7% | 79.3% | 19.4 | 14.7 | 1.44 | 8.70% | 9.2% |
| LLY NYSE Eli Lilly |
-1.02% | -15.3% | 414% | 64.5 | 36.4 | 1.21 | 58.2% | 18.9% |
| NOVN SW Novartis |
0.06% | 0.79% | 50.7% | 19.5 | 14.7 | 1.44 | 8.70% | 9.2% |
| GSK NYSE GlaxoSmithKline |
-5.43% | 3.38% | 45.1% | 19.1 | 8.73 | 0.38 | -25.2% | 3.11% |
| SFZN SW Siegfried Holding |
-4.81% | -9.99% | 101% | 24.2 | 23.6 | 1.48 | -42.4% | -29.3% |
| AZN NASDAQ AstraZeneca |
-2.46% | -6.31% | 40.1% | 27.9 | 15.4 | 0.93 | 72.4% | 45.1% |
| IPN PA Ipsen |
2.02% | -3.39% | 42.9% | 25.8 | 10.4 | 0.74 | -6.40% | -6.33% |
Performance Comparison: NMRA vs XLV vs S&P 500
XLV (Health Care Sector SPDR ETF) is the Sector Benchmark for NMRA
| Total Return (including Dividends) | NMRA | XLV | S&P 500 |
|---|---|---|---|
| 1 Month | 47.06% | -0.03% | 3.98% |
| 3 Months | 89.61% | -2.07% | 16.24% |
| 12 Months | -89.06% | -7.05% | 12.66% |
| 5 Years | -92.53% | 39.90% | 109.18% |
| Trend Score (consistency of price movement) | NMRA | XLV | S&P 500 |
|---|---|---|---|
| 1 Month | 47% | 35.5% | 91.4% |
| 3 Months | 74.2% | -14.5% | 97.5% |
| 12 Months | -89.4% | -79.5% | 46.7% |
| 5 Years | -72.7% | 87.6% | 84% |
| Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XLV | vs. S&P 500 |
|---|---|---|---|
| 1 Month | %th97.00 | 47.10% | 41.43% |
| 3 Month | %th92.00 | 93.61% | 63.12% |
| 12 Month | %th3.00 | -88.23% | -90.29% |
| 5 Years | %th21.50 | -92.87% | -94.75% |
FAQs
Does Neumora Therapeutics (NMRA) outperform the market?
No,
over the last 12 months NMRA made -89.06%, while its related Sector, the Health Care Sector SPDR (XLV) made -7.05%.
Over the last 3 months NMRA made 89.61%, while XLV made -2.07%.
Performance Comparison NMRA vs Indeces and Sectors
Above 0 means better perfomance compared to Symbol in this Timeframe
NMRA vs. Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 41.2% | 43.1% | -52.3% | -102% |
| US NASDAQ 100 | QQQ | 41.1% | 42.8% | -54.7% | -102% |
| German DAX 40 | DAX | 41.5% | 45.1% | -62.9% | -118% |
| Shanghai Shenzhen CSI 300 | CSI 300 | 39.7% | 41.9% | -54.2% | -109% |
| Hongkong Hang Seng | HSI | 40.4% | 44.5% | -73.6% | -123% |
| India NIFTY 50 | INDA | 42.6% | 46.4% | -52.1% | -86% |
| Brasil Bovespa | EWZ | 46.4% | 50.6% | -65.4% | -89% |
NMRA vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 41.8% | 44.2% | -57% | -114% |
| Consumer Discretionary | XLY | 40.1% | 43% | -45.1% | -106% |
| Consumer Staples | XLP | 43.4% | 46.8% | -51.3% | -97% |
| Energy | XLE | 39.6% | 45.9% | -42.5% | -88% |
| Financial | XLF | 42.1% | 42.7% | -54% | -113% |
| Health Care | XLV | 41.4% | 47.1% | -41.6% | -82% |
| Industrial | XLI | 40.4% | 41.6% | -57.3% | -112% |
| Materials | XLB | 41.3% | 43.3% | -50.9% | -92% |
| Real Estate | XLRE | 41% | 46.4% | -50.5% | -97% |
| Technology | XLK | 41.6% | 41.7% | -56.9% | -99% |
| Utilities | XLU | 40.9% | 44.2% | -55.2% | -112% |
| Aerospace & Defense | XAR | 38.8% | 37.2% | -72.8% | -139% |
| Biotech | XBI | 36.2% | 41.2% | -46.2% | -77% |
| Homebuilder | XHB | 39% | 37.8% | -42% | -85% |
| Retail | XRT | 40.8% | 41.9% | -49% | -96% |
NMRA vs. Commodities
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Oil | USO | 43% | 50.8% | -36.9% | -83% |
| Natural Gas | UNG | 40.7% | 57% | -27.1% | -95% |
| Gold | GLD | 41.6% | 48.3% | -69% | -127% |
| Silver | SLV | 38.3% | 42.2% | -71.6% | -113% |
| Copper | CPER | 31.8% | 33.6% | -70.1% | -111% |
NMRA vs. Bonds
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| iShares 20+ Years Bond | TLT | 42.5% | 46.5% | -46.9% | -85% |
| iShares High Yield Corp. Bond | HYG | 41.9% | 45.9% | -49.1% | -98% |